LMRA Lumera Corpration (MM)

Lumera Corporation (NASDAQ: LMRA), an emerging leader in the field of nanotechnology, announced today it will be showcasing the new design of its ProteomicProcessor� at PepTalk, a week long conference on protein research being held in San Diego from January 8 � 12, 2007. The company is also sponsoring a luncheon workshop at the conference for Dr. Joshua LaBaer of the Harvard Institute of Proteomics, in which he will discuss his research using Lumera�s ProteomicProcessor�. �The new design is the result of feedback from drug discovery scientists at several biopharmaceutical companies with whom we have ongoing discussions,� said Ron Dudek, Lumera Business Development Director. �The input we�ve received from the field has allowed us to incorporate important features that we believe will meet customer expectations.� Harvard�s Dr. LaBaer is a well-known researcher in the field of proteomics. He recently discussed his research in an article in the December 14 issue of Nature Magazine (http://www.nature.com/nature/journal/v444/n7121/index.html). Lumera executives were also interviewed in the article. �Josh LaBaer is a giant in his field and we�re very pleased to sponsor the luncheon workshop at PepTalk. We look forward to continuing our collaboration with him on the protein research he�s been developing,� said Dr. Tim Londergan, Director of Lumera�s Bioscience Business Unit. About Lumera Lumera is a leader in the emerging field of nanotechnology. The company designs proprietary molecular structures and polymer compounds for the bioscience and communications/computing industries, both of which represent large market opportunities. The company also has developed proprietary processes for fabricating such devices. For more information, please visit www.lumera.com. Certain statements contained in this release are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards and to develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products; and other risk factors identified from time to time in the company's SEC reports, including its Annual Report on Form 10-K, and its Quarterly Reports on Form 10-Q.